Table 5.
Relapse | ||||||
---|---|---|---|---|---|---|
Univariate Analysis | Multivariate Analysis | |||||
p-Value | Hazard Ratio | %95 CI | p-Value | Hazard Ratio | %95 CI | |
Age at Diagnosis | 0.585 | 1.005 | 0.987–1.023 | - | - | - |
Age of Onset of Lesions (Years) | 0.615 | 0.996 | 0.980–1.012 | - | - | - |
Time to Diagnosis (Months) | 0.032 * | 1.002 | 1.001–1.005 | 0.037 * | 1.003 | 1.001–1.005 |
Gender (Male) | 0.474 | 0.837 | 0.515–1.361 | - | - | - |
Patch/Patch + Plaque (Patch + Plaque) | 0.177 | 0.709 | 0.431–1.167 | - | - | - |
Morphological Findings | ||||||
Hyperpigmentation (Yes) | 0.211 | 0.691 | 0.387–1.233 | - | - | - |
Erythema (Yes) | 0.909 | 1.030 | 0.625–1.695 | - | - | - |
Pruritus (Yes = 1) | 0.515 | 1.176 | 0.722–1.914 | - | - | - |
Histopathological Findings | ||||||
Classic | 0.270 | 0.753 | 0.455–1.246 | - | - | - |
Folliculotropism | 0.579 | 1.392 | 0.433–4.477 | - | - | - |
CD8 (+) | 0.895 | 0.957 | 0.501–1.830 | - | - | - |
Stage at Diagnosis | ||||||
IB | 0.281 | 0.786 | 0.457–1.351 | - | - | - |
IIA | 0.518 | 0.892 | 0.460–1.733 | - | - | - |
T Stage at Diagnosis (T2) |
0.815 | 0.944 | 0.583–1.529 | - | - | - |
N Stage at Diagnosis | ||||||
Nx | 0.560 | 0.827 | 0.483–1.416 | - | - | - |
N1 | 0.492 | 0.815 | 0.412–1.613 | - | - | - |
β-2 Microglobulin (High) | 0.679 | 0.899 | 0.541–1.492 | - | - | - |
LDH (High) | 0.210 | 2.475 | 0.599–10.226 | - | - | - |
Eosinophilia (Yes) | 0.869 | 0.887 | 0.214–3.674 | - | - | - |
Initial Treatment Type | ||||||
Skin-directed | 0.787 | 1.098 | 0.557–2.165 | - | - | - |
Combined | 0.940 | 0.974 | 0.494–1.920 | - | - | - |
Initial Treatment | ||||||
NB-UVB | 0.001 * | 2.860 | 1.693–4.831 | 0.134 | 1.672 | 0.853–3.277 |
PUVA | 0.000 * | 0.375 | 0.101–0.628 | 0.034 * | 0.485 | 0.210–0.947 |
PUVA + IFN | 0.327 | 1.693 | 0.729–2.578 | - | - | - |
* p < 0.05 significant relationship. p > 0.05 no significant relationship; CI: confidence interval; LDH: lactate dehydrogenase; NB-UVB: Narrowband Ultraviolet B; PUVA: Psoralen + Ultraviolet A; IFN: Interferon.